The World Health Organization is committed to ensuring fair distribution of COVID-19 vaccine to ...

Cairo, 31 March 2021 – Syria, as one of the 92 countries eligible for COVID-19 vaccines under the COVAX Facility’s Advanced Market Commitment, stands ready to receive the first batch of the Astra Zeneca vaccine produced by the Serum Institute in India (AZ SII). This first batch is dedicated for 3% of the population and targets high-risk groups, prioritizing health workers and people over 55 years of age with co-morbidities. Under the COVAX Facility, in the first phase of COVID-19 vaccination, Syria is expected to receive 912 000 doses of the vaccine, including for northeast Syria, which accounts for 11% of the total Syrian population. An additional 224 000 doses of the vaccine will be allocated to northwest Syria.     “Allocation of the vaccines and its distribution across Syria is planned based on the latest population estimates by the UN OCHA Population Task Force. Our target is to vaccinate 20% of the population by the end of 2021, in addition to the health workers who will be vaccinated in the first phase of the COVID-19 vaccination campaign, and the elderly, people with co-morbidities, schoolteachers and other essential workers in the second phase,” said Dr Ahmed Al-Mandhari, WHO’s Regional Director for the Eastern Mediterranean.  Hospitals and public health care centres will be used as service delivery points to provide vaccinations, along with mobile teams all over the country. Services will be provided by trained hospital teams and rou...
Source: WHO EMRO News - Category: Middle East Health Source Type: news